A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males
- Registration Number
- NCT02411500
- Lead Sponsor
- Trevena Inc.
- Brief Summary
The primary objective of this study is to evaluate the pharmacokinetics of various TRV734 formulations in healthy male subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 18
Inclusion Criteria
- Healthy as determined by a responsible physician or trained qualified designee
- Males: 18 - 55 years inclusive at screening
- Capable of giving written informed consent
Exclusion Criteria
- Clinically significant conditions or history of fainting or syncope
- Medical or psychiatric illness that could interfere with the completion of treatment and follow up
- Major surgery within 4-weeks of screening
- Known difficulty with obtaining intravenous access
- History of sensitivity to the study medication, or intolerance to opioids, or a history of medication or other allergy that contraindicates their participation
- Use of prescription or non-prescription medications
- History of excessive alcohol use
- History of drug abuse within 6 months of screening
- Use of any illegal drug within 30 days of screening and throughout participation in the study
- History of smoking or use of nicotine containing products within 3 months of screening and throughout participation in the study
- Donation of blood or plasma 4 weeks prior to dosing
- Participation in a clinical trial and has received medication within 30 days
- Weight <50 kg or BMI outside range of 18-32 kg/m2
- Positive for HIV antibody, hepatitis B virus surface antigen, or hepatitis C virus
- Unwillingness to abstain from sexual intercourse with a pregnant or lactating woman and, if engaging in sexual intercourse with a female partner of child-bearing potential, use a condom and spermicide, in addition to having their female partner use another form of contraception, and abstain from sperm donation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Formulation A TRV734 - Formulation B TRV734 - Formulation C TRV734 - Formulation D TRV734 - Formulation E TRV734 - Formulation F TRV734 -
- Primary Outcome Measures
Name Time Method Evaluate the maximum observed plasma concentration (Cmax) 9-days Evaluate the apparent clearance (CL/F) 9-days Evaluate the time at which the maximum plasma concentration was observed (tmax) 9-days Evaluate the area under the plasma concentration-time curve from time 0 to the last measurable plasma concentration (AUC0-t) 9-days Evaluate the area under the plasma concentration-time curve from time 0 to time extrapolated to infinity (AUC0-inf) 9-days Evaluate the apparent elimination half-life (t1/2) 9-days
- Secondary Outcome Measures
Name Time Method Safety and tolerability as measured by clinical observations 9-days Safety and tolerability as measured by vital signs (BP, HR, RR and oral temperature) 9-days Safety and tolerability as measured by 12-lead ECGs 9-days Safety and tolerability as measured by cardiac telemetry monitoring 9-days Safety and tolerability as measured by adverse events 9-days Safety and tolerability as measured by oxygen saturation 9-days Safety and tolerability as measured by safety laboratory tests 9-days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of TRV734's pharmacokinetics in healthy males?
How does TRV734 compare to other opioid analgesics in terms of safety and efficacy profiles?
Are there specific biomarkers that correlate with TRV734's tolerability in phase 1 trials?
What adverse events are associated with TRV734 formulations and how are they managed?
What is the therapeutic potential of TRV734 in pain management compared to Trevena Inc.'s other drug candidates?